I am a Co-Founder of ANRis, Inc. Our game-changing siRNA suppresses only mutated mRNA, overcoming off-target effects to offer less burdensome treatments for cancer and CNS patients. Since 2023, we’ve achieved notable in vivo results and are moving toward non-clinical trials.